Literature DB >> 28074409

Management of Depression in Patients with Dementia: Is Pharmacological Treatment Justified?

Andrew H Ford1, Osvaldo P Almeida2.   

Abstract

Depression in the context of dementia is common and contributes to poorer outcomes in individuals and those who care for them. Non-pharmacological treatments are the preferred initial approach to managing these symptoms but data in support of these are scarce. There are a number of pharmacological treatment options available to clinicians but efficacy is uncertain and concern about potential side effects in an aging and vulnerable population needs to be taken into consideration. This review aims to provide a concise overview of pharmacological treatments for depression in dementia. Antidepressants are the mainstay of pharmacological treatment for clinically significant depression in the general population but evidence to support their use in dementia is mixed. Trials of antidepressants should generally be reserved for individuals with depression where the symptoms are distressing and surpass the threshold for major depression. Acetylcholinesterase inhibitors and memantine are effective in the symptomatic treatment of Alzheimer's disease but current evidence does not support their use to treat depressive symptoms in dementia. Similarly, antipsychotics and mood stabilizers have no proven efficacy for depression and the risk of adverse effects seems to outweigh any potential benefit. Pain can be a frequent problem in dementia and may have significant effects on behavior and mood. Preliminary evidence supports a role of adequate analgesia in improving mood in people with dementia.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28074409     DOI: 10.1007/s40266-016-0434-6

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  62 in total

Review 1.  Memantine for dementia.

Authors:  R McShane; A Areosa Sastre; N Minakaran
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

2.  Global prevalence of dementia: a Delphi consensus study.

Authors:  Cleusa P Ferri; Martin Prince; Carol Brayne; Henry Brodaty; Laura Fratiglioni; Mary Ganguli; Kathleen Hall; Kazuo Hasegawa; Hugh Hendrie; Yueqin Huang; Anthony Jorm; Colin Mathers; Paulo R Menezes; Elizabeth Rimmer; Marcia Scazufca
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

3.  Sertraline for the treatment of depression in Alzheimer disease.

Authors:  Paul B Rosenberg; Lea T Drye; Barbara K Martin; Constantine Frangakis; Jacobo E Mintzer; Daniel Weintraub; Anton P Porsteinsson; Lon S Schneider; Peter V Rabins; Cynthia A Munro; Curtis L Meinert; Constantine G Lyketsos
Journal:  Am J Geriatr Psychiatry       Date:  2010-02       Impact factor: 4.105

4.  Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses.

Authors:  Rajesh R Tampi; Deena J Tampi; Silpa Balachandran; Shilpa Srinivasan
Journal:  Ther Adv Chronic Dis       Date:  2016-07-15       Impact factor: 5.091

Review 5.  Thioridazine for dementia.

Authors:  V Kirchner; C A Kelly; R J Harvey
Journal:  Cochrane Database Syst Rev       Date:  2001

6.  A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial.

Authors:  D William Molloy; T I Standish; Q Zhou; G Guyatt
Journal:  Int J Geriatr Psychiatry       Date:  2012-06-21       Impact factor: 3.485

7.  Cognitive decline in patients with dementia as a function of depression.

Authors:  Michael A Rapp; Michal Schnaider-Beeri; Michael Wysocki; Elizabeth Guerrero-Berroa; Hillel T Grossman; Andreas Heinz; Vahram Haroutunian
Journal:  Am J Geriatr Psychiatry       Date:  2011-04       Impact factor: 4.105

8.  The efficacy of licensed-indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with Alzheimer's disease: systematic review and meta-analysis.

Authors:  I A Lockhart; M E Orme; S A Mitchell
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2011-07-20

9.  Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial.

Authors:  Bettina S Husebo; Clive Ballard; Reidun Sandvik; Odd Bjarte Nilsen; Dag Aarsland
Journal:  BMJ       Date:  2011-07-15

Review 10.  Identifying and Managing Pain in People with Alzheimer's Disease and Other Types of Dementia: A Systematic Review.

Authors:  Bettina S Husebo; Wilco Achterberg; Elisabeth Flo
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

View more
  10 in total

1.  Monitoring Behaviors of Patients With Late-Stage Dementia Using Passive Environmental Sensing Approaches: A Case Series.

Authors:  Wan-Tai M Au-Yeung; Lyndsey Miller; Zachary Beattie; Rose May; Hailey V Cray; Zachary Kabelac; Dina Katabi; Jeffrey Kaye; Ipsit V Vahia
Journal:  Am J Geriatr Psychiatry       Date:  2021-04-22       Impact factor: 4.105

2.  Tasks and Activities of an Effective Collaborative Dementia Care Management Program in German Primary Care.

Authors:  Franka Mühlichen; Bernhard Michalowsky; Anika Rädke; Moritz Platen; Wiebke Mohr; Jochen René Thyrian; Wolfgang Hoffmann
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

3.  Effectiveness of a peer-mediated educational intervention in improving general practitioner diagnostic assessment and management of dementia: a cluster randomised controlled trial.

Authors:  Dimity Pond; Karen Mate; Nigel Stocks; Jane Gunn; Peter Disler; Parker Magin; John Marley; Nerida Paterson; Graeme Horton; Susan Goode; Natasha Weaver; Henry Brodaty
Journal:  BMJ Open       Date:  2018-08-17       Impact factor: 2.692

4.  Drug Use before and after Initiating Treatment with Acetylcholinesterase Inhibitors.

Authors:  Anne Sverdrup Efjestad; Hege Ihle-Hansen; Vidar Hjellvik; Knut Engedal; Hege Salvesen Blix
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2019-04-26

Review 5.  Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates.

Authors:  Monika Marcinkowska; Joanna Śniecikowska; Nikola Fajkis; Paweł Paśko; Weronika Franczyk; Marcin Kołaczkowski
Journal:  CNS Drugs       Date:  2020-03       Impact factor: 5.749

Review 6.  Repurposing Cholinesterase Inhibitors as Antidepressants? Dose and Stress-Sensitivity May Be Critical to Opening Possibilities.

Authors:  Paul J Fitzgerald; Pho J Hale; Anjesh Ghimire; Brendon O Watson
Journal:  Front Behav Neurosci       Date:  2021-01-14       Impact factor: 3.558

Review 7.  Memantine in neurological disorders - schizophrenia and depression.

Authors:  Kamila Czarnecka; Jakub Chuchmacz; Przemysław Wójtowicz; Paweł Szymański
Journal:  J Mol Med (Berl)       Date:  2021-01-14       Impact factor: 4.599

8.  Concordance of self- and informant-rated depressive symptoms in nursing home residents with Dementia: cross-sectional findings.

Authors:  Julie L O'Sullivan; Roxana Schweighart; Sonia Lech; Eva-Marie Kessler; Christina Tegeler; Andrea Teti; Johanna Nordheim; Paul Gellert
Journal:  BMC Psychiatry       Date:  2022-04-05       Impact factor: 3.630

9.  Low continuation of antipsychotic therapy in Parkinson disease - intolerance, ineffectiveness, or inertia?

Authors:  Thanh Phuong Pham Nguyen; Danielle S Abraham; Dylan Thibault; Daniel Weintraub; Allison W Willis
Journal:  BMC Neurol       Date:  2021-06-24       Impact factor: 2.474

10.  Behavioural activation in nursing homes to treat depression (BAN-Dep): study protocol for a pragmatic randomised controlled trial.

Authors:  Diana Velasquez Reyes; Hema Patel; Nicola Lautenschlager; Andrew H Ford; Eleanor Curran; Rachael Kelly; Rhoda Lai; Terence Chong; Leon Flicker; David Ekers; Simon Gilbody; Christopher Etherton-Beer; Dina Lo Giudice; Kathryn A Ellis; Angelita Martini; Osvaldo P Almeida
Journal:  BMJ Open       Date:  2019-10-31       Impact factor: 2.692

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.